Recruiting

Testing a new oral medication for children with a specific type of brain tumor

Plain-English translation of NCT07158710 on ClinicalTrials.gov ↗ · Source last updated September 2025 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new oral medication called for children with recurrent brain tumors that have a specific genetic change (BRAF V600 mutation). The study will test different doses of the medication to see how safe it is and how well it works in children whose brain tumors have come back after previous treatments.

Many children with recurrent brain tumors don't have many treatment options, especially when the tumor has this particular genetic mutation. This medication is designed to target that specific mutation, which may help shrink the tumor or slow its growth.

Do you qualify?

You likely qualify if…

you are between 6 and 18 years old
you have been diagnosed with a recurrent brain tumor that has the BRAF V600 genetic mutation
your tumor has come back after previous treatments or your body couldn't tolerate earlier treatment
you are in reasonably good overall health (as measured by activity level and life expectancy of at least 3 months)
you are willing to use birth control during the study and for 90 days after the last dose if you could become pregnant

You likely don't qualify if…

you have another type of genetic mutation called NF1
you have had another cancer (besides skin cancer or thyroid cancer) in the past 2 years
you have serious heart problems, including irregular heartbeat or recent heart attack
you have a history of blood clots or a family history of clotting disorders
you have severe liver disease, kidney failure, or other serious organ problems

What participation looks like

You would take the medication by mouth at home, starting at a lower dose and potentially increasing over time as the study progresses. You would need to visit the clinic regularly so the doctors can check how you're responding and monitor for any side effects through blood tests and scans. The study has two phases: first, researchers will test different doses to find the right amount, and then they will expand testing at that dose in more patients with this type of tumor.

AI-generated summary from trial data · Aug 2, 2026 · Not medical advice

Trial locations(6 sites)

China

Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality

Department of Neuro-oncology, Cancer Center, Beijing Tiantan Hospital, Capital Medical University,Beijing, China, Beijing, Beijing Municipality

The first affiliated hospital of fujian medical university, Fuzhou, Fujian

Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong

The Third Bethune Hospital of Jilin University, Changchun, Jilin